Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of CDZ173 in APDS/PASLI
NCT02859727Phase 3Terminated
- Sponsor
- Pharming Group
- Start
- Sep 2016
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of leniolisib in activated phosphoinositide 3-kinase delta syndrome (APDS), sponsored by Pharming Group. Started Sep 2016; status: terminated.
02
Drugs
leniolisib
03
Conditions
activated phosphoinositide 3-kinase delta syndrome (APDS)
Beyond the preview
Go deeper on NCT02859727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859727.